Inventiva stock

IVA · Euronext Paris · EUR

Compare Inventiva
€2.94Change from previous close: −7.27%Absolute change: −€0.23

Close · November 20, 2026

Price history

−18.70% over the period

1 year: from €3.61 (November 20, 2025) to €2.94 (November 20, 2026), −18.70%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€2.94
October 30, 2026€3.18
September 30, 2026€3.30
August 31, 2026€4.05
July 31, 2026€3.80
June 30, 2026€3.22
May 29, 2026€4.28
April 30, 2026€4.31
March 31, 2026€4.75
February 27, 2026€5.49
January 30, 2026€5.00
December 31, 2025€3.94
November 28, 2025€3.66
November 20, 2025€3.61

At a glance

  • The company

    Clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis and other diseases

  • Latest results

    Quarter to June 30, 2026 · EPS -€0.18 (estimate -€0.47)

Where the price stands

52-wk low€2.57
52-wk high€6.20

−52.66% from the 52-week high

Analysts · 5 analysts

Average target€9.06+208.55% vs. price

Buy 5 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: Inventiva

Compared with similar companies: very high price, very weak momentum, and very low growth.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Inventiva is pricier than similar companies

Inventiva's Price/book: 13.6, +205% against the median of a group of 10 similar companies (4.45).

Compared with 11 similar companies

Inventiva's metrics compared with similar companies
MetricInventivaPosition in the groupBand
Operating margin-5,980.9%Low
ROE-989.1%Low
Debt/equity2.35High
Price/book13.6High
Net margin0.0%Middle

Grey band: the middle half of the group; tick: the median; dot: Inventiva. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€1.31M

Latest quarter · Q2 2026

Net income

-€69.47M

Latest quarter · Q2 2026

Quarterly net margin

-5,323.1%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€810.56M
EPS
-€0.53
Volume
408.93K
Daily trading
€1.87M
Dividend yield
0.00%

How Inventiva is changing

All results
  • Revenue grew 5.1% a year on average over the last 5 years

  • Operating margin fell from −316.6% to −1,965.5%

  • Shares outstanding up 451.4% in 5 years

Returns

Inventiva returns

€1,000 invested in Inventiva 5 years ago, on November 22, 2021, would be worth €249 today: −75.13% in total, −24.32% per year. This is the price return only: dividends are excluded.

PeriodInventivaCAC 40€1,000 becomes
1 month+1.21%+1.14%€1,012
6 months−33.75%−2.34%€663
Year to date−25.60%−2.72%€744
1 year−18.70%−0.67%€813
3 years−20.78%+9.39%€792
5 years−75.13%+11.58%€249

Over the last 6 months it has done better than 4% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Inventiva: technical analysis

Inventiva is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 81.1% below its all-time closing high (€15.56, January 21, 2021).

Trend
Downward
RSI (14 sessions)
43
Between 30 and 70
vs 200-session average
−26.66%

Active signals

  • The last session opened more than 3% below the previous close.

Support and resistance

Price areas where Inventiva has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€3.57+21.64%2 touches, last on August 4, 2026
  2. Resistance€3.36+14.48%2 touches, last on September 30, 2026
  3. Resistance€3.11+5.96%2 touches, last on November 2, 2026
  4. Last price€2.94
  5. Support€2.73−6.98%2 touches, last on September 25, 2026

Volatility and risk

Over the last year it has moved little with the CAC 40.

Beta (1 year) vs CAC 40
0.37
Volatility (60 sessions, annualised)
77.5%
Largest fall in the last year
−55.77%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Inventiva: seasonality

Average monthly price change over 10 years

+9.6%Jan−5.6%Feb−3.8%Mar−7.0%Apr+4.4%May+9.7%Jun−3.3%Jul+9.8%Aug−4.3%Sep+2.4%Oct+0.4%Nov+2.8%Dec

Over the last 10 years, the strongest month for Inventiva has been August: +9.81% on average, positive in 5 years out of 10. The weakest has been April: −6.97% on average, positive in 2 years out of 10. November, the current month, has been positive in 4 years out of 9 (+0.45% on average).

Show chart data
MonthAverageMedianPositive years
January+9.65%+7.00%7 of 9
February−5.56%0.00%4 of 9
March−3.80%−6.02%3 of 10
April−6.97%−9.28%2 of 10
May+4.35%+1.21%5 of 10
June+9.66%−6.93%3 of 10
July−3.34%−1.28%4 of 10
August+9.81%+2.55%5 of 10
September−4.32%−4.38%3 of 10
October+2.38%−2.44%4 of 10
November+0.45%−1.67%4 of 9
December+2.84%+7.06%5 of 9

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Inventiva and its competitors

Patients with metabolic dysfunction-associated steatohepatitis, known as MASH, and with mucopolysaccharidoses are among the groups this company develops treatments for, in France and in other countries. Its activity centres on orally administered small molecules aimed at MASH and other diseases, and its research pipeline is at clinical and pre-clinical stages. Lanifibranor, a peroxisome proliferator-activated receptor agonist, is in the NATiV3 Phase 3 trial in adult patients with MASH. Odiparcil targets mucopolysaccharidoses, and a pre-clinical TGF-β program addresses idiopathic pulmonary fibrosis.

Headquarters
Daix, France
Employees
87
Founded
2011
Chief executive
Andrew Obenshain
Inventiva and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
InventivaIVA$890.8M-5,980.9%—−33.75%
Pharming GroupPHARM$841.25M12.8%36.1−2.57%
PhilogenPHIL$905.96M79.1%3.67−5.63%
Basilea PharmaceuticaBSLN$1.07B24.2%18.1+35.06%
GubraGUBRA$730.02M-73.1%—−22.24%
Pharma MarPHM$1.1B21.3%14.7−41.56%

Same industry or related industries, similar size. Compare Inventiva with its competitors · Full profile